WO2016047849A1 - 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 - Google Patents
중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2016047849A1 WO2016047849A1 PCT/KR2014/010457 KR2014010457W WO2016047849A1 WO 2016047849 A1 WO2016047849 A1 WO 2016047849A1 KR 2014010457 W KR2014010457 W KR 2014010457W WO 2016047849 A1 WO2016047849 A1 WO 2016047849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mesenchymal stem
- hydrogel
- cell
- stem cell
- cells
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 81
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 30
- 238000011049 filling Methods 0.000 claims abstract description 14
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 38
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 14
- 108010049003 Fibrinogen Proteins 0.000 claims description 13
- 102000008946 Fibrinogen Human genes 0.000 claims description 13
- 229940012952 fibrinogen Drugs 0.000 claims description 13
- 108090000190 Thrombin Proteins 0.000 claims description 11
- 238000002659 cell therapy Methods 0.000 claims description 11
- 229960004072 thrombin Drugs 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229960005188 collagen Drugs 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical class CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 238000005406 washing Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 239000011148 porous material Substances 0.000 abstract description 7
- 238000005119 centrifugation Methods 0.000 abstract description 5
- 239000013543 active substance Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 2
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000009168 stem cell therapy Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 238000009580 stem-cell therapy Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 125000004386 diacrylate group Chemical group 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2539/00—Supports and/or coatings for cell culture characterised by properties
Definitions
- the present invention relates to a mesenchymal stem cell composition cultured in a hydrogel, and more particularly, to a human fat-derived mesenchymal stem cell-hydrogel composition and a method for preparing the same, and more particularly, to culture mesenchymal stem cells in a hydrogel.
- a mesenchymal stem cell composition cultured in a hydrogel and more particularly, to a human fat-derived mesenchymal stem cell-hydrogel composition and a method for preparing the same, and more particularly, to culture mesenchymal stem cells in a hydrogel.
- After washing and filling it into a syringe it can be directly administered, and does not require enzyme treatment in the preparation of final transplanted cells, and it is washed in a hydrogel state without a washing step using a centrifugal separation method.
- There is almost no, and there is a physiologically active substance in the hydrogel pores (pore) has the advantage of showing a therapeutic effect immediately after administration to the subject.
- first generation stem cell therapies are isolated cells obtained by treating proteolytic enzymes such as trypsin or dispase, thereby intercellularly binding because they selectively decompose all the proteins exposed to the cell membrane during proteolytic enzyme treatment. And basement membrane proteins, etc. are hardly maintained.
- animal-derived substances such as FBS are added to inactivate proteolytic enzymes, and washing-centrifugation is performed several times to remove them, typically 5 to 10% during one washing-centrifugation. A degree of cell loss occurs. Therefore, cell collection process using protease is a very inefficient method.
- mesenchymal stem cells are adherent cells, they die within 6 to 24 hours when separated into single cells, and have a low engraftment rate.
- WO 2006/004951 discloses a method for de novo in vivo synthesis of soft tissues of predetermined shape and scale from adult mesenchymal stem cells (MSCs) in biocompatible scaffolds and compositions prepared by such methods. It is starting.
- This document discloses a method of using a hydrogel polymer, more specifically polyethylene glycol diacrylate, as a biocompatible scaffold.
- the composition is intended for the recovery of soft tissue binding, and when polyethylene glycol diacrylate is used as a scaffold, it is intended that there should be almost no change in diameter. No process is disclosed or implied.
- Korean Patent No. 1,289,834 discloses a sphincter muscle regenerative cell therapy containing amniotic fluid-derived stem cells, and the cell therapy is injected into a hydrogel complex, specifically alginate / PF-127 / hyaluronic acid, to increase its effect. It is suggested that it can be. However, the document does not disclose that the yield can be improved by improving the process of collecting stem cells themselves.
- Korean Patent No. 684,940 discloses a method for differentiating mesenchymal stem cells into chondrocytes, and more specifically, a method of immobilizing mesenchymal stem cells on a mixed support containing fibrin / HA as a biodegradable polymer is disclosed. Is disclosed. However, the document only discloses that when fibrin / HA is used as a support, mesenchymal stem cells can be differentiated into chondrocytes without adding TGF-beta, which has been added for conventional cell differentiation.
- the enzymatic treatment during final cell preparation may damage intercellular binding and basal membrane protein, and cell loss at each stage of cell collection, washing, vial filling, and refilling with syringe in the vial.
- active substances such as collagen synthesized during cell culture are mostly removed.
- the cells are cultured in a hydrogel, washed and filled in a syringe to provide a composition that can be directly administered, thus eliminating the need for enzyme treatment in the preparation of the final transplanted cells and using a centrifugation method. Since the cell is washed in a hydrogel state without going through the cell, there is almost no cell loss, and the present invention is newly discovered that a bioactive substance is encapsulated in a hydrogel pore and shows an effective therapeutic effect immediately after administration to an individual. It was completed.
- the present invention is to use the mesenchymal stem cells isolated from human adipose tissue for the treatment of disease 1) to prevent the loss of cells in the process of collecting and culture the cells in a sufficient amount, 2) cells according to proteolytic enzyme treatment It is an object of the present invention to provide a method for preparing a cell composition and a composition obtained therefrom, the method of maximally improved to minimize the loss of cells at the target site.
- the cell composition prepared by the improved method is provided in a syringe for easy use.
- Cell-hydrogel prepared and filled with the present invention can be applied as a therapeutic agent for all diseases that can be administered locally using a needle of 20 to 25 gauge.
- the present invention provides a method for collecting stem cell-hydrogel using a syringe after culturing the adipose derived mesenchymal stem cells in a hydrogel.
- the mesenchymal stem cells may be autologous or allogeneic cells that are positive for CD29, CD44, CD73, CD90, and the like, and negative for CD34 and CD45.
- the hydrogel may be selected from the group consisting of fibrin glue, hyaluronic acid or derivatives thereof, gelatin, collagen, alginic acid, cellulose and pectin, wherein the concentration of fibrinogen forming fibrin glue is 0.4 To 1.8 mg / mL, more specifically 0.9 to 1.6 mg / mL.
- 100,000 to 2,000,000 stem cells are mixed with 1 mL of hydrogel to add 1 mL to 2 mL in a 12 to 24 well plate to make a gel and then cultured for 3 to 6 days by adding a medium.
- the medium may be DMEM medium containing 10% FBS and bFGF or EGF as presented in the prior patent (autologous and homogenous adipose derived stromal stem cell compositions for treating fistulas, registration no.
- the method for preparing a composition containing adipose derived mesenchymal stem cell-hydrogel according to the present invention is not required for enzyme treatment in the final transplant cell preparation process by using the cells after culturing in a hydrogel and washing them immediately after filling them in a syringe.
- Cells are washed in a hydrogel state without a washing step using a centrifugal separation method, so that there is almost no loss of cells, and a bioactive substance is encapsulated in the hydrogel pores, which shows a therapeutic effect immediately after administration to an individual. Very useful.
- the method for preparing a composition containing adipose derived mesenchymal stem cell-hydrogel according to the present invention does not go through the isolation (selection) step using proteolytic enzymes and thus loses cells according to the conventional cell collection process. Can be efficiently obtained.
- the stem cells obtained by the above method can be administered to the diseased area in a high activity state, the administered cells can remain in the target site until hydrogel is decomposed and absorbed, thereby continuing to exhibit a therapeutic effect.
- extracellular substrates such as collagen, laminin, fibronectin, and elastin, which are secreted from mesenchymal stem cells in the culture stage, are completely encapsulated in hydrogels, and thus, the therapeutic ability is remarkably superior to conventional therapeutic agents, and the treatment period can be shortened. That has a beneficial effect.
- fat-derived mesenchymal stem cell-hydrogel according to the present invention, the stem cells survive for more than a week in the hydrogel and maintain the fibroblast morphology significantly increased survival compared to conventional stem cell therapy, 1
- various growth factors and cytokines that promote cell growth and angiogenesis are continuously secreted, and a large amount of various extracellular substrates are secreted, and the secreted extracellular matrix stays in the hydrogel and is transplanted into the body. It has been shown that providing a variety of substrates can facilitate wound healing. In addition, it does not induce an immune response, but rather has the advantage of helping to heal wounds by inhibiting inflammation by inhibiting TNF-alpha, a proinflammatory agent secreted from activated immune cells.
- a is a cell-hydrogel form after culture
- b is a cell-hydrogel of a after filling the syringe
- c and d is a syringe
- Figure 2a is filled with a syringe filled with human adipose-derived mesenchymal stem cells cultured by mixing with fibrin gel prepared by diluting the fibrinogen and thrombin solution step by step and immediately observed the stem cell-hydrogel injected through a 23 gauge needle with an optical microscope The picture is (100 magnification). Dilution factor and concentration of fibrinogen and thrombin in the final hydrogel were indicated.
- Figure 2b is a photograph of the cell-hydrogel filled in the syringe was stored at 37 °C the same as the body temperature for 24 hours and then injected through a 23 gauge needle and observed under an optical microscope (100 magnification). Dilution factor and concentration of fibrinogen and thrombin in the final hydrogel were indicated.
- Figure 3 shows the cell recovery at each stage of collecting, washing, filling vials, and filling syringes with secondary culture cells according to the prior art, and collecting, washing, and filling the syringes with cells recovered in hydrogels. This graph shows the recovery rate.
- Figure 4 shows the survival of the cell-hydrogel (Example 3) filled in a syringe by incubating in a vial (Comparative Example 1) and a hydrogel secondary culture in accordance with the prior art by staining with AO / EtBr It is a photograph.
- Figure 5 shows the cells contained in the cell suspension (second comparison), the cell suspension prepared in the secondary culture, collection, washing, and filling (Comparative Example 1) and the cell-hydrogel (Example 3) incubated, washed, and in a hydrogel according to the prior art It is a graph showing the amount of collagen type I, which is an external substance, quantified by enzyme-linked immunosorbent assay.
- the present invention provides a method for preparing a composition containing fat-derived mesenchymal stem cells-hydrogel, and when using the method of the present invention, the cells are cultured in a hydrogel, washed and immediately filled with a syringe, and then used.
- the enzyme treatment is not necessary in the final transplantation cell preparation, and the cell is washed in a hydrogel state without undergoing a centrifugal separation step.
- a bioactive substance is encapsulated in the hydrogel pores. It is very useful because it shows a therapeutic effect immediately after administration to an individual.
- the present invention (A) culturing the adipose derived mesenchymal stem cells; (b) mixing the cultured adipose derived mesenchymal stem cells with a hydrogel solution to form a gel; And (c) relates to a method for producing a mesenchymal stem cell-hydrogel composition comprising the step of culturing the gel.
- the hydrogel is fibrin glue, hyaluronic acid, gelatin, collagen, alginic acid, chitosan, cellulose, pectin, 2-hydroxyethyl methacrylate derivatives and copolymers thereof, polyethylene oxide and polyvinyl alcohol
- Any one or two or more complexes selected from the group consisting of hydrogels may be used, and more specifically, the hydrogels may be any one selected from the group consisting of fibrin glue, hyaluronic acid, gelatin, collagen, alginic acid, cellulose and pectin or Two or more complexes may be used, and more specifically fibrin glue may be used.
- the fibrin glue may include fibrinogen at a concentration of 0.4 to 1.8 mg / mL, and more specifically, may include fibrinogen at a concentration of 0.9 to 1.6 mg / mL.
- the fibrin glue may comprise thrombin at a concentration of 1 to 300 IU / mL, specifically 5 to 30 IU / mL, and more particularly at a concentration of 10 to 15 IU / mL can do. Within this range no problems arise in terms of cell proliferation and cell-hydrogel adhesion.
- the step (c) may further comprise the step (d) of filling the mesenchymal stem cell-hydrogel composition in the ampoule, vial or syringe.
- the fat-derived mesenchymal stem cell-hydrogel composition prepared according to the method of the present invention can be directly administered locally using a needle of 20 to 25 gauge.
- the number of cells counted in the mesenchymal stem cell-hydrogel filled in the ampoule, vial or syringe prepared in step (d) is a cell counting the mesenchymal stem cells obtained in step (c) Or 70% or more, more specifically 80% or more of the number.
- the present invention provides a cell therapy agent containing the mesenchymal stem cell-hydrogel composition prepared by the above method as an active ingredient.
- the term "cell therapeutic agent” refers to a pharmaceutical product used for the purpose of treatment, diagnosis, and prevention as cells and tissues prepared by isolation, culture, and special chewing from humans. In particular, it is used for the purpose of treatment, diagnosis, and prevention through a series of actions such as proliferating and screening living autologous, allogeneic, or heterologous cells in vitro or altering biological characteristics of cells in order to restore the function of cells or tissues.
- a drug refers to a drug.
- Cell therapy agents are classified into somatic cell therapy and stem cell therapy according to the degree of differentiation of cells, and the present invention relates to adipose derived stem cell therapy.
- the term "individual” means any animal including a human who has already developed or can develop a disease that can be prevented or treated through the administration of a cell therapy agent according to the present invention.
- Adipose tissue is usually obtained by liposuction, but is not limited thereto.
- Adipose-derived mesenchymal stem cells were isolated from adipose tissue obtained by liposuction as follows: Adipose tissue was washed 3-4 times with the same volume of PBS to remove blood. The same volume of collagenase solution as adipose tissue was added and reacted in a 37 ° C. water bath. It was transferred to a centrifuge tube and centrifuged at 20 ° C., 1500 rpm for 10 minutes. The supernatant fat layer was removed, and the lower collagenase solution was carefully separated so as not to shake. After the substrate medium was suspended and centrifuged for 5 minutes at 20 °C, 1200 rpm.
- the subsidence was the stromal-vascular fraction, and the supernatant was removed.
- the stromal-vascular fractions were suspended in substrate medium and inoculated in culture vessels and incubated in 37 ° C., 5% CO 2 incubator for 24 hours. After removing the culture medium, the cells were washed with phosphate buffer, and the substrate medium or the growth medium containing basic fibroblast growth factor (bFGF) at a concentration of 1 ng / ml in the substrate medium, or the epidermal growth factor (EGF) in the substrate medium. Proliferation was performed using the medium contained at a ng / ml concentration.
- Adipose-derived mesenchymal stem cells were grown to about 80-90% of the culture vessel and obtained by separating them into single cells by trypsin treatment.
- Thrombin solution 400-600 IU was added at a ratio of 1:10, 1:20, 1:40 to 5 ⁇ 10 5 adipose derived mesenchymal stem cells / mL obtained in Example 1 above.
- Fibrinogen 71.5-126.5 mg / mL was prepared by diluting 1:20, 1:40, 1:80, respectively.
- 500-700 uL of the cell suspension containing fibrinogen and thrombin were added to each well of a 12 well plate using a duploject syringe system. When the gel was completely hardened, the culture medium containing 10% FBS, 1 ng / mL bFGF was added and then incubated for 5 days at 37 °C, 5% CO 2 incubator.
- DMEM fetal calf serum
- FIG. 1A is a photograph taken by moving a cell-hydrogel cultured in 12well to a dish and maintained during the incubation period after the hydrogel was formed.
- FIG. 1B shows that the cell-hydrogel is filled in the syringe, and the gel state remains intact even after the cell-hydrogel is filled in the syringe.
- FIG. 1C illustrates a process of injecting a cell-hydrogel after connecting a 23 gauge needle to a cell-hydrogel-filled syringe
- FIG. 1D illustrates a cell-hydrogel injected through a 23 gauge needle still in the hydrogel form. It can be seen that it is maintained.
- Figure 2a is a photograph taken under a microscope after filling the syringe with the cell-hydrogel prepared in each ratio and injected into the plate through a 23 gauge needle.
- the fibringlu concentration was diluted, the cells proliferated well.
- the fibringluin final concentration was 0.9 to 1.6 mg / mL or 0.4 to 0.8 mg / mL, the cells proliferated well and the cells and fibringlu hydrogels were well fused. Giving. No significant difference according to thrombin concentration was observed.
- Figure 2b is a microscopic picture of the cell-hydrogel prepared in each ratio was injected into the syringe and injected into the plate through a 23 gauge needle left at 37 °C for 24 hours.
- the final concentration of fibrinogen is 1.8 ⁇ 3.2 mg / mL and 0.4 ⁇ 0.8 mg / mL
- the cells and hydrogel are almost separated, but when the final concentration of fibrinogen is 0.9 ⁇ 1.6 mg / mL It shows good compatibility in the gel. No significant difference according to thrombin concentration was observed.
- the thrombin solution was added at a ratio of 1:20 to 5 ⁇ 10 5 cells / mL of the adipose derived mesenchymal stem cells obtained in Example 1, and fibrinogen was diluted 1:40 and prepared according to Example 2, After washing, the syringe was filled.
- trypsin-IDT is added to isolate it into single cells, and the enzyme is inactivated with DMEM containing fetal bovine serum and placed in a centrifuge tube. Pooled and centrifuged at 1,500 rpm. After removing the supernatant, the cells were suspended by adding DMEM to remove fetal bovine serum, and then centrifuged again at 1,500 rpm, and the supernatant was removed. A total of three washes and in the last step the cells were suspended in an appropriate volume of cell suspension and then filled in vials. The filled cells were transferred to a 1 mL syringe connected to a 23 gauge needle.
- Figure 3a is a graph showing the cell recovery rate at each step compared to the initial collection step (trypsin-IDT inactivation) when preparing the cell therapy according to the conventional manufacturing method (Comparative Example 1) 10 to 25% in each step After the final filling of the syringe, only about 30% of the cells were recovered compared to the initial collection stage.
- Figure 3b is a graph showing the cell collection rate at the first stage of collection (after completion of the culture) in each step when prepared according to the manufacturing method (Example 3) of the present invention 1 to 5% of each step was reduced, the final More than 80% of the cells were recovered by syringe filling.
- cells filled in vials prepared by the conventional method maintained a high survival rate of 95% or more at 0 hours, but at 24 hours, the cell membranes were destroyed and cell membranes were destroyed, thereby preventing the cells from maintaining their morphology. At 72 hours, almost all of the cells were killed and not observed. On the other hand, the cells incubated in cell-hydrogel survived until 7 days and maintained the fibroblast morphology.
- the amount of collagen type I was analyzed by enzyme-linked immunosorbent assay (ELISA) after culturing in a hydrogel according to Example 3 and dissolving the cell-hydrogel filled in a 1 mL syringe by enzymatic treatment.
- ELISA enzyme-linked immunosorbent assay
- the cell suspension cultured according to the conventional cell therapy preparation method contained little collagen, but the cell-hydrogel contained more than 3 ug / mL collagen.
- composition containing fat-derived mesenchymal stem cell-hydrogel according to the present invention, by culturing the cells in a hydrogel, washed and immediately filled with a syringe to use the enzyme treatment in the final transplant cell preparation process, centrifugation There is almost no loss of cells as it is washed in a hydrogel state without going through a washing step using a separation method and the like, and a bioactive substance is contained in the hydrogel pores, which shows a therapeutic effect immediately after administration to an individual. Very useful.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (11)
- (a) 지방유래 중간엽줄기세포를 배양하는 단계;(b) 상기 배양된 지방유래 중간엽줄기세포와 하이드로겔 용액을 혼합하여 겔을 형성시키는 단계; 및(c) 상기 겔을 배양하는 단계를 포함하는,중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,하이드로겔은 피브린 글루, 히알루론산, 젤라틴, 콜라겐, 알긴산, 키토산, 셀룰로오스, 펙틴, 2-히드록시에틸 메타아크릴레이트 유도체 및 이의 공중합체, 폴리에틸렌 옥사이드 및 폴리비닐 알코올로 이루어진 그룹으로부터 선택되는 어느 하나 또는 2종 이상의 복합체인 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,하이드로겔은 피브린 글루인 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,피브린 글루는 0.4 내지 1.8 mg/mL의 농도의 피브리노겐을 포함하는 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,피브린 글루는 0.9 내지 1.6 mg/mL의 농도의 피브리노겐을 포함하는 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,피브린 글루는 1 내지 300 I.U./mL 농도의 트롬빈을 포함하는 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,피브린 글루는 10 내지 15 I.U./mL 농도의 트롬빈을 포함하는 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항에 있어서,단계 (c) 이후, 중간엽줄기세포-하이드로겔 조성물을 앰플, 바이알 또는 주사기에 충진하는 단계 (d)를 추가로 포함하는 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제8항에 있어서,단계 (d)에서 제조된 앰플, 바이알 또는 주사기에 충진된 중간엽줄기세포-하이드로겔에서 카운팅한 세포수가, 단계 (c)에서 수득된 중간엽줄기세포를 카운팅한 세포수의 70% 이상인 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제8항에 있어서,단계 (d)에서 제조된 앰플, 바이알 또는 주사기에 충진된 중간엽줄기세포-하이드로겔에서 카운팅한 세포수가, 단계 (c)에서 수득된 중간엽줄기세포를 카운팅한 세포수의 80% 이상인 것을 특징으로 하는, 중간엽줄기세포-하이드로겔 조성물의 제조방법.
- 제1항 내지 제10항 중 어느 한 항의 방법으로 제조된 중간엽줄기세포-하이드로겔 조성물을 유효성분으로 함유하는, 세포치료제.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14902879.7A EP3199169A4 (en) | 2014-09-22 | 2014-11-03 | Composition containing mesenchymal stem cell-hydrogel and method for producing the composition |
US15/513,247 US20170304366A1 (en) | 2014-09-22 | 2014-11-03 | Composition containing mesenchymal stem cell-hydrogel and method for producing the composition |
CN201480082128.5A CN107073037A (zh) | 2014-09-22 | 2014-11-03 | 包含间充质干细胞‑水凝胶的组合物及其制备方法 |
JP2017515684A JP6452807B2 (ja) | 2014-09-22 | 2014-11-03 | 間葉系幹細胞−ヒドロゲルを含有する組成物及びこれの製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0125981 | 2014-09-22 | ||
KR1020140125981A KR101613478B1 (ko) | 2014-09-22 | 2014-09-22 | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016047849A1 true WO2016047849A1 (ko) | 2016-03-31 |
Family
ID=55581358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/010457 WO2016047849A1 (ko) | 2014-09-22 | 2014-11-03 | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170304366A1 (ko) |
EP (1) | EP3199169A4 (ko) |
JP (1) | JP6452807B2 (ko) |
KR (1) | KR101613478B1 (ko) |
CN (1) | CN107073037A (ko) |
WO (1) | WO2016047849A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018226648A1 (en) | 2017-06-05 | 2018-12-13 | Mayo Foundation For Medical Education And Research | Methods and materials for culturing, proliferating, and differentiating stem cells |
WO2020067774A1 (ko) * | 2018-09-28 | 2020-04-02 | 이화여자대학교 산학협력단 | 활액막 유래 중간엽 줄기세포 및 그의 용도 |
US11679180B2 (en) | 2016-12-07 | 2023-06-20 | Mayo Foundation For Medical Education And Research | Methods and materials for using fibrin supports for retinal pigment epithelium transplantation |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101885729B1 (ko) * | 2016-07-21 | 2018-08-06 | 의료법인 성광의료재단 | 지방조직 유래 중간엽 줄기세포 및 히알루론산 유도체를 포함하는 조성물 및 그를 제조하는 방법 |
US20200360444A1 (en) | 2017-12-28 | 2020-11-19 | Kaneka Corporation | Cell population including adhesive stem cells, production method therefor and pharmaceutical composition |
US20200368291A1 (en) | 2017-12-28 | 2020-11-26 | Kaneka Corporation | Cell population including adhesive stem cells, production method therefor and pharmaceutical composition |
AU2019231273A1 (en) * | 2018-03-06 | 2020-09-24 | Epibone, Inc. | Injectable off-the- shelf cartilage, tendon, and ligament repair compositions and methods of use |
CN109182249B (zh) * | 2018-09-17 | 2022-04-19 | 宇润全成生物科技(北京)有限公司 | 一种在体修复用细胞移植的支架材料的制备方法 |
KR20200065892A (ko) * | 2018-11-30 | 2020-06-09 | 오가노이드사이언스 주식회사 | 오가노이드의 생체 이식용 조성물 |
EP3936607A4 (en) | 2019-03-08 | 2023-01-04 | Kaneka Corporation | MASS CULTURE OF PLURIPOTENTS STEM CELLS |
US20220175666A1 (en) * | 2019-03-21 | 2022-06-09 | Anterogen Co., Ltd. | Injection formulation composition containing mesenchymal stem cell-hydrogel and method for preparing, freezing and defrosting same |
EP3943065A4 (en) * | 2019-03-21 | 2022-12-14 | Anterogen Co., Ltd. | INJECTION FORMULATION COMPOSITION CONTAINING A MESENCHYMATOUS STEM CELL HYDROGEL AND METHOD OF PREPARING, FREEZING AND THAWING THEREOF |
CN113663132B (zh) * | 2021-07-20 | 2022-10-18 | 湖南美柏生物医药有限公司 | 脂肪组织再生水凝胶及其制备方法和应用 |
WO2023072161A1 (zh) * | 2021-10-26 | 2023-05-04 | 江阴司特易生物技术有限公司 | 包含间充质干细胞和水凝胶的组合物及其应用 |
CN114557956A (zh) * | 2021-12-30 | 2022-05-31 | 江苏拓弘生物科技有限公司 | 一种负载脐带间充质干细胞的温敏型水凝胶及其制备方法 |
CN114316167B (zh) * | 2022-01-24 | 2022-11-22 | 湖北沃德利派生物科技有限公司 | 可负载间充质干细胞上清液成分的可注射光增强自愈合水凝胶及其制备方法 |
CN114904043B (zh) * | 2022-04-28 | 2023-07-21 | 深圳市儿童医院 | 复合水凝胶及其制备方法和应用 |
KR20240014436A (ko) * | 2022-07-25 | 2024-02-01 | 아주대학교산학협력단 | 기계적 강도가 조절된 기질을 포함하는 줄기세포 배양용조성물 및 이의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004951A2 (en) * | 2004-06-30 | 2006-01-12 | The Board Of Trustees Of The University Of Illinois | Poly (ethylene glycol) - diacrylate- (pegda) - crosslinked hydrogels comprising adipogenic mesenchymal stem cells |
KR100684940B1 (ko) * | 2005-10-14 | 2007-02-20 | (주)필미아젠 | 피브린/ha를 함유하는 혼합 지지체를 이용한 중간엽줄기세포를 연골세포로 분화시키는 방법 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641913B1 (en) * | 2003-06-27 | 2016-01-06 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
AU2005267748B2 (en) * | 2004-07-30 | 2012-09-20 | The Brigham And Women's Hospital, Inc. | Amorphous cell delivery vehicle treated with physical/physicochemical stimuli |
JP2006346420A (ja) * | 2005-06-13 | 2006-12-28 | Univ Nagoya | 移植材料及び骨質改善剤 |
US8741326B2 (en) * | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
KR20080103637A (ko) * | 2007-05-25 | 2008-11-28 | 주식회사 알앤엘바이오 | 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물 |
EP2173859B1 (en) * | 2007-06-29 | 2016-05-11 | Makoto Funaki | Soft gel systems in modulating stem cell development |
AU2009214044B2 (en) * | 2008-02-15 | 2014-08-14 | Bone Therapeutics | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
WO2009154840A2 (en) * | 2008-03-27 | 2009-12-23 | Neostem, Inc. | Compositions and methods using stem cells in cutaneous wound healing |
US20100028311A1 (en) * | 2008-07-09 | 2010-02-04 | Baxter International Inc. | Using of scaffold comprising fibrin for delivery of stem cells |
WO2011067983A1 (ja) * | 2009-12-03 | 2011-06-09 | 株式会社セルシード | 脂肪細胞シート、その三次元構造体、及びそれらの製造方法 |
WO2011116072A1 (en) * | 2010-03-16 | 2011-09-22 | Escape Therapeutics, Inc. | Hybrid hydrogel scaffold compositions and methods of use |
JP5843189B2 (ja) * | 2011-03-15 | 2016-01-13 | 国立大学法人名古屋大学 | Sdf−1阻害剤を含有した軟骨組織再生用組成物 |
CN103687940B (zh) * | 2011-07-06 | 2016-10-12 | 希司托赛尔有限公司 | 用于间充质干细胞的处理方法及其在氧化应激相关疾病治疗中的应用 |
ES2791769T3 (es) * | 2011-11-09 | 2020-11-05 | Tufts College | Espumas de fibroína de seda inyectables y usos de la misma |
US20140227233A1 (en) * | 2013-01-29 | 2014-08-14 | University Hospitals Cleveland Medical Center | Treatment of Urinary Incontinence with Regenerative Glue |
KR101495281B1 (ko) * | 2014-01-10 | 2015-02-24 | (주)안트로젠 | 피부 재생 또는 상처 치유를 위한 중간엽 줄기세포-하이드로겔-생분해성 또는 중간엽 줄기세포-하이드로겔-비분해성 지지체 조성물 |
-
2014
- 2014-09-22 KR KR1020140125981A patent/KR101613478B1/ko active IP Right Grant
- 2014-11-03 US US15/513,247 patent/US20170304366A1/en not_active Abandoned
- 2014-11-03 JP JP2017515684A patent/JP6452807B2/ja active Active
- 2014-11-03 WO PCT/KR2014/010457 patent/WO2016047849A1/ko active Application Filing
- 2014-11-03 EP EP14902879.7A patent/EP3199169A4/en active Pending
- 2014-11-03 CN CN201480082128.5A patent/CN107073037A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004951A2 (en) * | 2004-06-30 | 2006-01-12 | The Board Of Trustees Of The University Of Illinois | Poly (ethylene glycol) - diacrylate- (pegda) - crosslinked hydrogels comprising adipogenic mesenchymal stem cells |
KR100684940B1 (ko) * | 2005-10-14 | 2007-02-20 | (주)필미아젠 | 피브린/ha를 함유하는 혼합 지지체를 이용한 중간엽줄기세포를 연골세포로 분화시키는 방법 |
Non-Patent Citations (2)
Title |
---|
ISABELLE CATELAS ET AL.: "Human Mesenchymal Stem Cell Proliferation and Osteogenic Differentiation in Fibrin Gels in Vitro", TISSUE ENGINEERING, vol. 12, no. 8, 2006, pages 2385 - 2396, XP055369911 * |
YUGUO LEI ET AL.: "The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels", BIOMATERIALS, vol. 32, 2011, pages 39 - 47, XP027493687, DOI: doi:10.1016/j.biomaterials.2010.08.103 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11679180B2 (en) | 2016-12-07 | 2023-06-20 | Mayo Foundation For Medical Education And Research | Methods and materials for using fibrin supports for retinal pigment epithelium transplantation |
WO2018226648A1 (en) | 2017-06-05 | 2018-12-13 | Mayo Foundation For Medical Education And Research | Methods and materials for culturing, proliferating, and differentiating stem cells |
EP3635094A4 (en) * | 2017-06-05 | 2021-03-17 | Mayo Foundation for Medical Education and Research | PROCESSES AND MATERIALS FOR THE CULTURE, PROLIFERATION AND DIFFERENTIATION OF STEM CELLS |
WO2020067774A1 (ko) * | 2018-09-28 | 2020-04-02 | 이화여자대학교 산학협력단 | 활액막 유래 중간엽 줄기세포 및 그의 용도 |
Also Published As
Publication number | Publication date |
---|---|
US20170304366A1 (en) | 2017-10-26 |
EP3199169A1 (en) | 2017-08-02 |
KR20160034690A (ko) | 2016-03-30 |
EP3199169A4 (en) | 2018-06-06 |
KR101613478B1 (ko) | 2016-04-19 |
JP6452807B2 (ja) | 2019-01-16 |
JP2017529362A (ja) | 2017-10-05 |
CN107073037A (zh) | 2017-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016047849A1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 | |
US20230405180A1 (en) | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-undegradable support composition for skin regeneration or wound healing | |
KR101585032B1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 | |
RU2608641C2 (ru) | Применение стромальных стволовых клеток жировой ткани для лечения свищей | |
KR101389850B1 (ko) | 심장전구세포의 배양방법 및 그 용도 | |
Alatyyat et al. | Umbilical cord stem cells: Background, processing and applications | |
CN106520676B (zh) | 从人胎盘羊膜制备人羊膜上皮细胞的方法及其应用 | |
WO2015105356A1 (ko) | 순수 영양막층으로부터 유래된 줄기세포 및 이를 포함하는 세포치료제 | |
KR20060110637A (ko) | 분화된 어린 지방 세포와 생분해성 중합체의 이식에 의한신체의 부피 대체 방법 | |
WO2002063962A1 (en) | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells | |
AU2002243980A1 (en) | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells | |
KR102473820B1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 주사형 조성물 및 이의 제조, 동결 및 해동방법 | |
US20090305406A1 (en) | Method of cultivation of human mesenchymal stem cells, particularly for the treatment of non-healing fractures, and bioreactor for carrying out this cultivation method | |
KR100811537B1 (ko) | 지방조직 치료제의 조성, 이들 제조방법 및 그의 전달방법 | |
KR20150029280A (ko) | 당뇨성 창상 치유를 위한 자가 및 동종의 지방 유래 중간엽 줄기세포 조성물 | |
CN106606512B (zh) | 一种用于治疗心肌梗死的混合细胞制剂及制备方法与应用 | |
KR20210145705A (ko) | 염증성 질환의 예방 또는 치료용 중간엽줄기세포 배양액 및 이의 제조방법 | |
JP2013511314A (ja) | 神経組織再生のための移植片組成物と、その製造および使用法 | |
Kitala et al. | The isolation and production of the ready-to-use product (the amniotic stem cell culture) in accordance with good manufacturing practice regulations | |
CN104232570A (zh) | 建立单克隆间充质干细胞的方法及其应用 | |
KR20060107897A (ko) | 이식용 연골 조성물 | |
WO2020190094A1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 주사형 조성물 및 이의 제조, 동결 및 해동방법 | |
WO2018225703A1 (ja) | 分化誘導細胞の調製方法 | |
Shi et al. | Advancements in culture technology of adipose-derived stromal/stem cells: implications for diabetes and its complications | |
RU2272638C1 (ru) | Биотрансплантат, способ его получения и способ лечения хронического гепатита и цирроза печени (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14902879 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017515684 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15513247 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014902879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014902879 Country of ref document: EP |